OANDA and GAIN Capital are currently in the midst of a patent infringement lawsuit, and they have yet to finalize the details regarding the deposition of a key individual associated with GAIN. The case, which is being heard in the New Jersey District Court, centers around allegations made by OANDA against GAIN Capital Holdings, Inc. and GAIN Capital Group, LLC concerning the infringement of U.S. patents related to currency trading technologies.
While both companies have agreed to schedule depositions, issues remain regarding the extent of the depositions. Specifically, GAIN Capital will take the second day of Dr. Michael Stumm’s deposition on July 29, 2025, while OANDA’s second deposition session is set for August 7, 2025. However, the specifics of each party’s deposition must still be negotiated and confirmed.
In the background of this litigation, the involved parties have had disputes over deposition procedures, including a recent disagreement concerning the deposition of the former CEO of ActForex, who is also related to the case.
The patent infringement claims brought forth by OANDA focus on two specific patents that involve systems for trading currencies via a computer network. These patents outline various components and methods necessary for effective currency trading, including systems architecture such as server front-ends, databases, transaction servers, and pricing engines.
The first patent, often referred to as the ’336 Patent, details a sophisticated structure essential for trading currency over networks, highlighting components like transaction management and risk evaluation mechanisms. Similarly, the second patent, known as the ’311 Patent, covers comparable systems and methodologies designed for online currency trades. Both patents emphasize the technological innovations that facilitate trading processes in financial markets, outlining not just the system requirements but also the methods and software involved in currency transactions over computer networks.
As the case moves forward, these disagreements on deposition specifics and the underlying patent claims will likely shape the legal proceedings and potential outcomes for both companies involved.